The End Tuberculosis Strategy of the World Health Organization (WHO) calls for the early diagnosis of tuberculosis (TB) and use of universal drug susceptibility testing (DST) in order to start patients on the most effective treatment regimen as early as possible. DST using solid or liquid media and rapid molecular-based DST to detect drug-resistant TB are available and endorsed by WHO; however, in 2015, WHO reported that among new cases of bacteriologically confirmed TB, only 12% had undergone DST . Most national tuberculosis programmes do not offer universal DST , and in 2015, 12 countries reported no capacity to perform phenotypic DST  while 28 countries had neither in-country capacity nor a linkage with a partner laboratory for second-line DST.
A new multinational study of the noncommercial MODS assay shows excellent performance in detecting M/XDR-tuberculosis http://ow.ly/FAEJ308OiOw
The authors would like to acknowledge the site investigators, Valeriu Crudu (Phthisiopneumology Institute), Tommie Victor (Stellenbosch University) and Camilla Rodriques (P.D. Hinduja National Hospital and Medical Research Centre), as well as their clinical and laboratory staff for their assistance in acquiring and testing patient specimens.
Support statement: Data and funding for this project were provided by the NIAID-funded GCDD (grant #U01-AI082229; PI: A. Catanzaro). T.C. Rodwell was partly funded under NIH grant number P30 AI036214-20 and receives salary support from FIND, a non-profit organisation. The terms of this arrangement have been reviewed and approved by the UCSD. Funding information for this article has been deposited with the Open Funder Registry.
Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com
- Received September 23, 2016.
- Accepted December 16, 2016.
- Copyright ©ERS 2017